东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01875 东曜药业-B

休市中 02-06 16:08:02

4.250

-0.040

-0.93%

最高4.290	最低4.200	成交量130.28万
今开4.250	昨收4.290	日振幅2.10%
总市值32.85亿	流通市值32.84亿	总股本7.73亿
成交额552.74万	换手率0.17%	流通股本7.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01875","market":"HK","secType":"STK","nameCN":"东曜药业-B","latestPrice":4.25,"timestamp":1770365282494,"preClose":4.29,"halted":0,"volume":1302800,"delay":0,"changeRate":-0.009324009324009333,"floatShares":772787887,"shares":773000000,"eps":0.047927,"marketStatus":"休市中","change":-0.04,"latestTime":"02-06 16:08:02","open":4.25,"high":4.29,"low":4.2,"amount":5527400,"amplitude":0.020979,"askPrice":4.25,"askSize":202800,"bidPrice":4.21,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-0.006,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":7,"adr":0,"listingDate":1573142400000,"exchange":"SEHK","adjPreClose":4.29,"openAndCloseTimeList":[[1770341400000,1770350400000],[1770354000000,1770364800000]],"volumeRatio":0.630883357763841,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01875","defaultTab":"news","newsList":[{"id":"2609998375","title":"东曜药业-B02月05日主力净流入58.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2609998375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609998375?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:15","pubTimestamp":1770279336,"startTime":"0","endTime":"0","summary":"02月05日, 东曜药业-B股价涨3.62%，报收4.29元，成交金额1920.8万元，换手率0.58%，振幅5.80%，量比3.20。东曜药业-B今日主力资金净流入58.0万元，上一交易日主力净流出0万元。该股近5个交易日上涨3.37%，主力资金累计净流出171.4万元；近20日主力资金累计净流出1424.9万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205161802a6d6414e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205161802a6d6414e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","01875"],"gpt_icon":0},{"id":"1187055074","title":"药明合联生物技术(2268)、东曜药业(1875)联合公告：延迟寄发自愿有条件现金要约综合文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1187055074","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187055074?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:55","pubTimestamp":1770213323,"startTime":"0","endTime":"0","summary":"药明合联生物技术有限公司与东曜药业股份有限公司联合宣布，原定于2026年2月4日前寄发的针对东曜药业自愿有条件现金要约的综合文件将推迟至2026年2月13日或之前寄发。该文件包括要约人及公司提供的要约文件与受要约董事会通函。东曜药业股东与购股权持有人需在作出是否接纳要约的决定前，仔细阅读综合文件及其中包含的独立董事委员会推荐和独立财务顾问意见，并在必要时寻求专业意见。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875"],"gpt_icon":0},{"id":"2608892645","title":"东曜药业-B02月02日遭主力抛售175.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608892645","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608892645?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:15","pubTimestamp":1770020155,"startTime":"0","endTime":"0","summary":"02月02日, 东曜药业-B股价跌1.46%，报收4.06元，成交金额1145.4万元，换手率0.36%，振幅1.94%，量比1.22。东曜药业-B今日主力资金净流出175.4万元，上一交易日主力净流出54.0万元。该股近5个交易日下跌0.49%，主力资金累计净流出199.2万元；近20日主力资金累计净流出1482.9万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202162226a6c97657&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202162226a6c97657&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01875"],"gpt_icon":0},{"id":"2606520499","title":"东曜药业-B01月27日主力净流入30.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2606520499","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606520499?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:15","pubTimestamp":1769501729,"startTime":"0","endTime":"0","summary":"01月27日, 东曜药业-B股价涨2.70%，报收4.19元，成交金额2267.0万元，换手率0.70%，振幅5.15%，量比1.29。东曜药业-B今日主力资金净流入30.2万元，上一交易日主力净流出117.1万元。该股近5个交易日下跌0.95%，主力资金累计净流出1503.2万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1253.5万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127161748a6b21e3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127161748a6b21e3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01875"],"gpt_icon":0},{"id":"2605489160","title":"东曜药业-B01月21日主力净流出593.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2605489160","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605489160?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:15","pubTimestamp":1768983357,"startTime":"0","endTime":"0","summary":"01月21日, 东曜药业-B股价跌0.71%，报收4.20元，成交金额2456.6万元，换手率0.76%，振幅2.84%，量比0.26。东曜药业-B今日主力资金净流出593.3万元，上一交易日主力净流入69.1万元。该股近5个交易日上涨68.80%，主力资金累计净流出343.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出372.5万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121163428a444bf9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121163428a444bf9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01875","BK1161"],"gpt_icon":0},{"id":"2604999951","title":"大摩：药明合联提全购东曜药业-B 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2604999951","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604999951?lang=zh_cn&edition=full","pubTime":"2026-01-20 10:51","pubTimestamp":1768877472,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，药明合联(02268)提全购东曜药业-B(01875)，交易引起部分投资者对收购理据的疑问。大摩对药明合联评级为“增持”，目标价88港元。报告指，2025年上半年，东曜药业录得收入4.89亿元人民币(下同)，盈利400万元; 同期对比，药明合联的收入和盈利分别为27.01亿元及7.46亿元。过去，东曜药业专注于肿瘤药物，进入2020年代后，公司将资源重新配置，转型为以ADC(抗体-药物偶联物)为重点的CDMO模式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120105452a43f1232&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120105452a43f1232&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","01875"],"gpt_icon":0},{"id":"2604133079","title":"东曜药业-B(01875)委任中毅资本为独立财务顾问","url":"https://stock-news.laohu8.com/highlight/detail?id=2604133079","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604133079?lang=zh_cn&edition=full","pubTime":"2026-01-19 20:28","pubTimestamp":1768825684,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)发布公告，中毅资本有限公司(一家根据证券及期货条例可从事第1类(证券交易)及第6类(就机构融资提供意见)受规管活动的持牌法团)已获委任为独立财务顾问，以就该等要约(尤其是该等要约是否属公平合理以及应否接纳该等要约)向独立董事委员会提供意见。独立财务顾问的委任已根据收购守则规则第2.1条获独立董事委员会的批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01875","BK1161"],"gpt_icon":0},{"id":"2604681188","title":"大和：予药明生物(02269)“买入”评级 预料东曜药业(01875)将维持上市地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2604681188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604681188?lang=zh_cn&edition=full","pubTime":"2026-01-19 14:36","pubTimestamp":1768804588,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，药明生物(02269)及药明合联(02268)宣布将以最高约28亿元的代价提出全面收购要约，收购东曜药业(01875)至少60%的股份，预料完成后东曜药业将维持上市地位。药明合联则预期，是次收购有助拓展业务，并取得在中国的额外营运生产能力，可进一步丰富项目组合及扩大客户群，巩固在ADC合同研发及生产组织领域的领先市场地位。大和目前给予药明生物投资评级为“买入”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","02269"],"gpt_icon":0},{"id":"2603954830","title":"一哥”3年砸100亿圈地，千亿市场正在“变天","url":"https://stock-news.laohu8.com/highlight/detail?id=2603954830","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603954830?lang=zh_cn&edition=full","pubTime":"2026-01-16 09:49","pubTimestamp":1768528160,"startTime":"0","endTime":"0","summary":"这一收购价较东曜药业2025年12月22日收盘价溢价99%，较过去30个交易日平均收盘价更是溢价114.67%。其二，强化市场地位。从“拼价格”到“拼体系”中国的ADC CDMO，正在“变身”。皓元医药2025年前三季度前端业务营收14.5亿元，同比增长31%，后端业务营收6亿元，同比增长16.9%。其承接的XDC项目超70个，截至2025年6月，在22家ADC出海的国内公司中，服务了95%以上出","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116095150a4c9c462&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116095150a4c9c462&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","02268","BK1191","06821","LU2488822045.USD","BK1141","01875"],"gpt_icon":0},{"id":"2603982881","title":"药明系再扩产能，溢价一倍收购上市药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2603982881","media":"健识局","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603982881?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:30","pubTimestamp":1768480210,"startTime":"0","endTime":"0","summary":"1月14日晚，药明系几家上市公司抛出一份联合公告：药明合联以现金每股4港元的价格，向东曜药业提出全面收购要约。消息发布后，1月15日，东曜药业股价大幅拉升最高77%。另外，截至去年上半年，东曜药业新增14个ADC项目，累计至169个项目。当然，药明合联已经未雨绸缪，表示收购完成后，继续维持东曜药业的上市地位。但同时，也将持续检讨东曜药业的营运，保留对公司业务和营运作出认为必要或适当的任何变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115203521a71eaac6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115203521a71eaac6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","SG9999014674.SGD","01875","BK1141","LU2488822045.USD"],"gpt_icon":0},{"id":"2603266625","title":"东曜药业-B(01875)1月15日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2603266625","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603266625?lang=zh_cn&edition=full","pubTime":"2026-01-15 08:45","pubTimestamp":1768437900,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)发布公告，公司股份将于2026年1月15日上午9时正起恢复买卖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1161","BK1574"],"gpt_icon":0},{"id":"2603678877","title":"超30亿港元！药明收购一家CDMO公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2603678877","media":"细胞与基因治疗...","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603678877?lang=zh_cn&edition=full","pubTime":"2026-01-15 08:37","pubTimestamp":1768437451,"startTime":"0","endTime":"0","summary":"1月14日，药明生物发布公告，宣布一项收购要约，旗下子公司药明合联将收购东曜药业。于本公告日期，东曜药业已发行股份总数为772,787,887股。也就是说股本总价值约为30.91亿港元。根据收购守则，股份要约将提呈予全体要约股份持有人。股东、购股权持有人及潜在投资者务请留意，于本声明作出后，要约人将不得提高股份要约价或注销价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115085637953cd0c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115085637953cd0c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1576","LU0051755006.USD","SG9999002562.SGD","LU0516423174.USD","SG9999002463.SGD","LU0516422366.SGD","LU0140636845.USD","LU0348735423.USD","LU1688375341.USD","LU1794554557.SGD","LU0327786744.USD","LU0307460666.USD","02269","LU0348825331.USD","LU0320764599.SGD","LU0823426308.USD","LU0823426480.USD","LU0359201612.USD","LU0588546209.SGD","LU0516422440.USD","LU2039709279.SGD","BK1141","LU0181495838.USD","LU0819121731.USD","LU0856984785.SGD","LU0417516738.SGD","LU0359202008.SGD","LU0039217434.USD","LU0417516902.SGD","LU0516422952.EUR","LU0326950275.SGD","LU0043850808.USD","LU1720050803.USD","LU0979878070.USD","LU1242518857.USD","LU0572944931.SGD","LU0456827905.SGD","LU0052750758.USD","LU3063872942.SGD","LU0516423091.SGD","IE00B0JY6N72.USD","01875","LU0708995583.HKD","BK1521","LU1242518931.SGD","LU1880383366.USD","BK1610","LU0456846285.SGD"],"gpt_icon":0},{"id":"2603462820","title":"智通港股早知道 | 财政部召开财政金融协同促内需会议 白宫宣布对特定半导体等加征25%关税","url":"https://stock-news.laohu8.com/highlight/detail?id=2603462820","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603462820?lang=zh_cn&edition=full","pubTime":"2026-01-15 07:40","pubTimestamp":1768434028,"startTime":"0","endTime":"0","summary":"参加会议的包括国务院有关部门和单位、省级财政部门、财政部各地监管局以及相关经办机构。美国白宫宣布对特定半导体等加征25%关税美国白宫14日宣布，从15日起对部分进口半导体、半导体制造设备和衍生品加征25%的进口从价关税。根据该通知书，市监总局已根据中华人民共和国反垄断法开始对本公司进行调查。经本公司财务部门初步测算，预计2025年度实现归属于上市公司股东的扣除","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a7a093e7059d2a399d631855b31ce739","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","03759","BK1189","02269","BK1502","LU1720050803.USD","BK1571","SOXX","BK4585","BK1247","BK1516","BK1584","BK1617","BK1147","BK1564","09961","BK1591","BK1610","ZLAB","BK1589","02268","TCOM","01875","BK1521","300759","BK1142","WXXWY","BK1501","09688","LU1794554557.SGD","BK4588","SMH","BK1615"],"gpt_icon":1},{"id":"2603157617","title":"港股公告掘金 | 东曜药业-B获药明合联溢价约99%提现金要约 1月15日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2603157617","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603157617?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:05","pubTimestamp":1768403110,"startTime":"0","endTime":"0","summary":"重大事项：龙旗科技(09611)1月14日至1月19日招股 拟全球发售5225.91万股H股和黄医药(00013)宣布SACHI III期研究结果于《柳叶刀 (The Lancet)》发表东阳光药(06887)推出面向PROTAC机制的AI智能研发平台 持续深化AI战略布局东曜药业-B(01875)获药明合联(02268)溢价约99%提现金要约 1月15日复牌维立志博-B(09887)：维利信(P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1634259557.SGD","06030","BK1191","LU1720050803.USD","01875","BK1516","06887","LU0264606111.USD","BK1141","LU1497733557.USD","BK1564","LU1634259391.SGD","LU1497733631.SGD","LU2488822045.USD","BK1521","SG9999014674.SGD","LU0572940350.SGD","HK0000252160.HKD","LU0456827905.SGD","02268","00998","BK1231","BK1147","LU1497734951.SGD","LU1522347837.USD","BK1560","BK1574","LU0051755006.USD","LU0572939691.SGD","LU1794554557.SGD","BK1161","09887","HK0000252152.HKD","HK0000500386.USD","LU0210526637.USD"],"gpt_icon":0},{"id":"2603617932","title":"东曜药业-B(01875)获药明合联(02268)溢价约99%提现金要约 1月15日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2603617932","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603617932?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:02","pubTimestamp":1768402952,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 及要约人药明合联联合公布，于2026年1月14日，董事会获要约人告知，花旗将为及代表要约人作出自愿有条件现金要约，以每股要约股份4港元的价格收购全部已发行股份，并注销全部尚未行使购股权。要约价较股份于未受干扰日在联交所所报收市价每股2.01港元溢价约99.00%。公司已向联交所申请自2026年1月15日上午九时正起恢复股份于联交所买卖。要约人拟于完成后维持股份于联交所上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东曜药业-B获药明合联溢价约99%提现金要约，1月15日复牌","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2488822045.USD","BK1574","SG9999014674.SGD","BK1141","02268","01875"],"gpt_icon":1},{"id":"1191815089","title":"东曜药业-B向港交所提交申请 股票将于1月15日恢复交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1191815089","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191815089?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:57","pubTimestamp":1768402630,"startTime":"0","endTime":"0","summary":"东曜药业-B（股票代码：01875）已正式向香港联合交易所提交申请，请求自2024年1月15日起恢复公司股份的买卖交易。此次申请标志着公司在满足相关监管要求后，正积极推动股票交易的正常化进程。若获批复，投资者将可于下周一重新在公开市场进行该股票的买卖操作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01875","BK1161","BK1574"],"gpt_icon":0},{"id":"1147379811","title":"东曜药业-B：药明合联拟全面收购公司非其持有之全部已发行股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1147379811","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147379811?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:55","pubTimestamp":1768402526,"startTime":"0","endTime":"0","summary":"东曜药业-B（BIODLINK-B）近日披露重大收购要约，药明合联（WuXi XDC Cayman）计划收购公司全部已发行股份中非其已持有的部分。\n此次要约标志着药明合联对东曜药业-B的战略整合迈出关键一步，或将重塑公司股权结构。市场密切关注此次收购对东曜药业-B未来业务发展和市场定位的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01875"],"gpt_icon":0},{"id":"2595279964","title":"停牌！CEO离任，业绩下滑，biotech有新交易？","url":"https://stock-news.laohu8.com/highlight/detail?id=2595279964","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595279964?lang=zh_cn&edition=full","pubTime":"2025-12-30 00:13","pubTimestamp":1767024785,"startTime":"0","endTime":"0","summary":"任何文章转载需得到授权。药融圈监测显示：东曜药业-B发布公告，公司的股份将于2025年12月29日上午九时正起短暂停止买卖。此前在8月12日，东曜药业发布截至2025年6月30日的中期业绩公告，业绩显示公司营业收入为4.89亿元，同比下降6%。CDMO/CMO业务收入为7730万元，同比下降32%，主要是由于部分关键项目尚未达到交付节点。2016 年 10 月至 2025 年 10 月于东曜药业股份有限公司担任副总经理、首席科学家、首席执行官、执行董事。离开后任职纳微。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230001828a486c140&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230001828a486c140&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01875","BK1161"],"gpt_icon":0},{"id":"2593434752","title":"东曜药业-B12月22日主力净流出14.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2593434752","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593434752?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:15","pubTimestamp":1766391313,"startTime":"0","endTime":"0","summary":"12月22日, 东曜药业-B股价跌0.99%，报收2.01元，成交金额61.7万元，换手率0.04%，振幅4.43%，量比0.93。东曜药业-B今日主力资金净流出14.1万元，上一交易日主力净流出0万元。该股近5个交易日上涨1.52%，主力资金累计净流入32.9万元；近20日主力资金累计净流入100.6万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222161548a6c084bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222161548a6c084bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01875","BK1161","BK1574"],"gpt_icon":0},{"id":"2593121463","title":"东曜药业-B(01875)授出1335万股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593121463","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593121463?lang=zh_cn&edition=full","pubTime":"2025-12-21 18:15","pubTimestamp":1766312109,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)公布，2025年12月19日，管理委员会已议决根据2024年受限制股份奖励计划作出授出，共涉及1335万股奖励股份，每股奖励股份0.6港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01875","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.totbiopharm.com.cn","stockEarnings":[{"period":"1week","weight":0.0316},{"period":"1month","weight":0.7},{"period":"3month","weight":1.2727},{"period":"6month","weight":0.7932},{"period":"1year","weight":1.4011},{"period":"ytd","weight":0.7}],"compareEarnings":[{"period":"1week","weight":-0.0302},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0121},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.2713},{"period":"ytd","weight":0.0363}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"东曜药业股份有限公司是一家临床阶段生物制药公司，主要从事开发及商业化肿瘤药物及疗法。该公司的主营业务在中华人民共和国从事抗肿瘤药物的研究与开发、生产及营销、合约开发生产组织（CDMO）/合约生产组织（CMOJ）业务以及自主开发生物药物的对外许可。该公司拥有针对各类癌症的在研肿瘤药物管线，当中包括单克隆抗（mAb）及抗体偶联药物（ADC）。该公司已建立起一个集发现、产程开发、质量管理临床前及临床开发以及商业规模的生产基地和销售及营销能力于一体的综合内部平台。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":0.036017},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.032683},{"month":3,"riseRate":0.5,"avgChangeRate":-0.024422},{"month":4,"riseRate":0.833333,"avgChangeRate":0.069994},{"month":5,"riseRate":0.666667,"avgChangeRate":0.07905},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.001367},{"month":7,"riseRate":0.333333,"avgChangeRate":0.023634},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.052288},{"month":9,"riseRate":0.666667,"avgChangeRate":0.011349},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.041625},{"month":11,"riseRate":0,"avgChangeRate":-0.064081},{"month":12,"riseRate":0.714286,"avgChangeRate":0.042078}],"exchange":"SEHK","name":"东曜药业-B","nameEN":"BIODLINK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东曜药业-B,01875,东曜药业-B股票,东曜药业-B股票老虎,东曜药业-B股票老虎国际,东曜药业-B行情,东曜药业-B股票行情,东曜药业-B股价,东曜药业-B股市,东曜药业-B股票价格,东曜药业-B股票交易,东曜药业-B股票购买,东曜药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}